Axon Enterprise, Inc. (NASDAQ:AXON) Receives $488.67 Consensus PT from Analysts

Shares of Axon Enterprise, Inc. (NASDAQ:AXON) have received an average rating of “Buy” from the thirteen ratings firms that are currently covering the company, MarketBeat reports. Thirteen investment analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokerages that have covered the stock in the last year is $488.67.

A number of brokerages have issued reports on AXON. Needham & Company LLC raised their target price on Axon Enterprise from $525.00 to $600.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Morgan Stanley upgraded shares of Axon Enterprise from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $500.00 to $700.00 in a report on Tuesday, December 3rd. The Goldman Sachs Group increased their target price on shares of Axon Enterprise from $385.00 to $441.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd. Northland Securities boosted their price target on shares of Axon Enterprise from $365.00 to $550.00 and gave the company an “outperform” rating in a report on Monday, November 11th. Finally, JMP Securities raised their price objective on Axon Enterprise from $430.00 to $500.00 and gave the stock a “market outperform” rating in a research note on Thursday, October 31st.

Insider Activity

In other news, Director Caitlin Elizabeth Kalinowski sold 450 shares of Axon Enterprise stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $604.07, for a total value of $271,831.50. Following the completion of the transaction, the director now owns 6,929 shares of the company’s stock, valued at $4,185,601.03. This trade represents a 6.10 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Michael Garnreiter sold 1,000 shares of the company’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $437.98, for a total transaction of $437,980.00. Following the completion of the sale, the director now directly owns 26,259 shares in the company, valued at approximately $11,500,916.82. The trade was a 3.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 51,545 shares of company stock worth $31,159,317 in the last quarter. Corporate insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Axon Enterprise

Institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC increased its stake in shares of Axon Enterprise by 2.0% during the third quarter. Geode Capital Management LLC now owns 1,782,828 shares of the biotechnology company’s stock worth $710,103,000 after purchasing an additional 35,320 shares during the period. Westfield Capital Management Co. LP grew its holdings in Axon Enterprise by 12.2% in the 3rd quarter. Westfield Capital Management Co. LP now owns 1,175,328 shares of the biotechnology company’s stock valued at $469,661,000 after buying an additional 127,769 shares in the last quarter. Champlain Investment Partners LLC increased its position in Axon Enterprise by 13.9% during the 3rd quarter. Champlain Investment Partners LLC now owns 682,420 shares of the biotechnology company’s stock worth $272,695,000 after buying an additional 83,265 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Axon Enterprise by 1.6% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 561,263 shares of the biotechnology company’s stock worth $224,281,000 after buying an additional 9,090 shares in the last quarter. Finally, Groupama Asset Managment bought a new stake in shares of Axon Enterprise in the third quarter valued at about $200,000. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Stock Up 0.8 %

NASDAQ:AXON opened at $601.06 on Tuesday. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32. Axon Enterprise has a 12-month low of $241.72 and a 12-month high of $698.67. The stock’s fifty day simple moving average is $593.68 and its 200-day simple moving average is $440.17. The firm has a market capitalization of $45.83 billion, a P/E ratio of 155.31, a P/E/G ratio of 14.19 and a beta of 1.04.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.